Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Werewolf TherapeuticsHOWL -4.02%32 Equity-to-Asset is 0.67 as of Jun. 2026, which is 5% above its 10-year median of 0.64. GuruFocus rates HOWL with a GF Score™ of 32/100 and a GF Value™ of $3.78 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 1,411 Biotechnology companies, Werewolf Therapeutics ranks worse than 50.89% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Werewolf Therapeutics Equity-to-Asset Related Terms
Werewolf Therapeutics Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Werewolf Therapeutics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HOWL vs CVM, MRKR, ZIVO: Equity-to-Asset Comparison
For the Biotechnology subindustry, Werewolf Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Werewolf Therapeutics Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Werewolf Therapeutics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Werewolf Therapeutics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Werewolf Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Werewolf Therapeutics (HOWL) has a Equity-to-Asset of 0.67 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Werewolf Therapeutics and its competitors. This is near median its historical median of 0.64. According to the industry distribution chart, Werewolf Therapeutics ranks #718 out of 1411 companies in the Biotechnology industry, placing it in the top 50.9%.
Is Werewolf Therapeutics' Equity-to-Asset too high?
Werewolf Therapeutics' current Equity-to-Asset of 0.67 is near median its 10-year median of 0.64. The Biotechnology industry median Equity-to-Asset is 0.68. Werewolf Therapeutics' value of 0.67 is 1.5% below this industry median. Based on the distribution chart, Werewolf Therapeutics ranks #718 out of 1411 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Werewolf Therapeutics has a GF Score™ of 32/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Werewolf Therapeutics' Equity-to-Asset compare to CVM and MRKR?
According to the Biotechnology industry distribution chart, Werewolf Therapeutics ranks #718 out of 1411 companies for Equity-to-Asset. This places Werewolf Therapeutics in the lower half of its industry. The industry median Equity-to-Asset is 0.68. Werewolf Therapeutics' value of 0.67 is 1.5% below this benchmark. While the company's 10-year median is 0.64 vs. the industry median of 0.68, Werewolf Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Werewolf Therapeutics's current Equity-to-Asset of 0.67 is 1.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Werewolf Therapeutics and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Werewolf Therapeutics's current Equity-to-Asset is 0.67, which is near median its own 10-year median of 0.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Werewolf Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Werewolf Therapeutics (HOWL) is currently considered Possible Value Trap. The stock's GF Value™ is $3.78, compared to a current price of $0.38 — trading 89.9% below its estimated fair value. The current Equity-to-Asset is 0.67, which is near median its 10-year median of 0.64 and 1.5% below the Biotechnology industry median of 0.68. Werewolf Therapeutics' overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Werewolf Therapeutics (HOWL), the current Equity-to-Asset is 0.67 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Werewolf Therapeutics (HOWL) Overvalued in 2026?
Based on GuruFocus' analysis, Werewolf Therapeutics stock appears to be undervalued.
The current stock price of $0.38 is trading 89.9% below its estimated GF Value™ of $3.78.
GuruFocus considers Werewolf Therapeutics to be Possible Value Trap.
Key valuation signals for HOWL:
Equity-to-Asset: 0.67 (near median its 10-year median of 0.64)
GF Value™: $3.78 vs. price of $0.38 (89.9% below fair value)
Industry Position: 1.5% below the Biotechnology median (#718 of 1411)
No single metric tells the full story. See the HOWL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.
32GF Score
Get the complete analysis for HOWL
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HOWL has been successfully added to your 
